Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Outpatients With Mild to Moderate COVID-19 Illness

NCT04870606 is registered in ClinicalTrials.gov with Suzhou Kintor Pharmaceutical Inc, as lead sponsor.

NCT NCT04870606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04870606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Outpatients With Mild to Moderate COVID-19 Illness
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Phase
Phase 3
Overall status
Completed
Start date
March 5, 2021
Completion date
April 6, 2022
Enrollment
733 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy and safety